文献速递心力衰竭与心肌病

成人暴发性COVID-19相关心肌炎的表型异质性

Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

单中心回顾性分析38例因疑似暴发性COVID-19相关心肌炎入住ICU的成人患者,比较符合与不符合MIS-A标准的两组患者在临床特征、预后及免疫学指标上的差异,发现MIS-A-患者病情更重、死亡率更高且免疫特征不同。

要点

  • 符合MIS-A标准的暴发性COVID-19相关心肌炎患者占66%。
  • MIS-A-患者更可能需要VA-ECMO支持且院内死亡率更高。
  • 两型患者细胞因子谱和自身抗体存在差异,提示不同病理生理机制。

核心结论

  • MIS-A+与MIS-A-暴发性COVID-19相关心肌炎是两种不同表型,临床表现、预后和免疫学特征均不同。

研究设计与样本

  • 单中心回顾性分析,纳入2020年3月至2021年6月期间因疑似暴发性COVID-19相关心肌炎入住26张床位ICU的连续38例成人患者。

主要发现

  • ICU内器官衰竭治疗包括多巴酚丁胺79%、去甲肾上腺素60%、机械通气50%、VA-ECMO 42%和肾脏替代治疗29%。
  • 院内死亡率为13%。
  • MIS-A-患者相比MIS-A+患者,COVID-19症状发作至心肌炎间隔更短、左心室射血分数更低、ICU内器官衰竭发生率更高。
  • MIS-A-患者更可能需要VA-ECMO支持(92% vs 16%;P < 0.0001),且院内死亡率更高(31% vs 4%)。
  • MIS-A+患者循环IL-22、IL-17和TNF-α水平更高,而MIS-A-患者IFN-α2和IL-8水平更高。

临床怎么用

  • 临床中应区分MIS-A+与MIS-A-两种表型,以指导暴发性COVID-19相关心肌炎患者的个体化管理。

局限性

  • 单中心回顾性研究,样本量较小(38例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adults who have been infected with SARS-CoV-2 can develop a multisystem inflammatory syndrome (MIS-A), including fulminant myocarditis. Yet, several patients fail to meet MIS-A criteria, suggesting the existence of distinct phenotypes in fulminant COVID-19-related myocarditis. OBJECTIVES: This study sought to compare the characteristics and clinical outcome between patients with fulminant COVID-19-related myocarditis fulfilling MIS-A criteria (MIS-A+) or not (MIS-A-). METHODS: A monocentric retrospective analysis of consecutive fulminant COVID-19-related myocarditis in a 26-bed intensive care unit (ICU). RESULTS: Between March 2020 and June 2021, 38 patients required ICU admission (male 66%; mean age 32 ± 15 years) for suspected fulminant COVID-19-related myocarditis. In-ICU treatment for organ failure included dobutamine 79%, norepinephrine 60%, mechanical ventilation 50%, venoarterial extracorporeal membrane oxygenation 42%, and renal replacement therapy 29%. In-hospital mortality was 13%. Twenty-five patients (66%) met the MIS-A criteria. MIS-A- patients compared with MIS-A+ patients were characterized by a shorter delay between COVID-19 symptoms onset and myocarditis, a lower left ventricular ejection fraction, and a higher rate of in-ICU organ failure, and were more likely to require mechanical circulatory support with venoarterial extracorporeal membrane oxygenation (92% vs 16%; P < 0.0001). In-hospital mortality was higher in MIS-A- patients (31% vs 4%). MIS-A+ had higher circulating levels of interleukin (IL)-22, IL-17, and tumor necrosis factor-α (TNF-α), whereas MIS-A- had higher interferon-α2 (IFN-α2) and IL-8 levels. RNA polymerase III autoantibodies were present in 7 of 13 MIS-A- patients (54%) but in none of the MIS-A+ patients. CONCLUSION: MIS-A+ and MIS-A- fulminant COVID-19-related myocarditis patients have 2 distinct phenotypes with different clinical presentations, prognosis, and immunological profiles. Differentiating these 2 phenotypes is relevant for patients' management and further understanding of their pathophysiology.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Barhoum P, Pineton de Chambrun M, Dorgham K, et al. Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults. J Am Coll Cardiol. 2022. PMID: 35863846. doi:10.1016/j.jacc.2022.04.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。